SCHEMBL4175603

SCHEMBL4175603

CC(=O)Nc1cccc(C=C2c3ccccc3CCc3ccccc32)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 1/20 0.65
PGR P06401 1/20 0.65
NR3C2 P08235 1/20 0.65
AR P10275 1/20 0.65
NPC1 O15118 5/20 0.60
RAB9A P51151 5/20 0.60
KMT2A Q03164 2/20 0.54
CYP1A2 P05177 4/20 0.50
MAOA P21397 2/20 0.50
ADRA2A P08913 1/20 0.50
SLC6A2 P23975 1/20 0.50
HTR2C P28335 1/20 0.50
SLC6A4 P31645 1/20 0.50
HTR2B P41595 1/20 0.50
CYP2C9 P11712 2/20 0.49
ALDH1A1 P00352 4/20 0.45
KDM4E B2RXH2 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
PSD A5PKW4 1/20 0.45
HSD17B10 Q99714 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14092271 0.87 NR3C1 (0.76) NR3C1PGRNR3C2ARNPC1
SCHEMBL4157827 0.87 AR (0.62) NR3C1PGRNR3C2ARNPC1
SCHEMBL4162477 0.85 KMT2A (0.72) NR3C1PGRNR3C2ARNPC1
SCHEMBL13803303 0.85 NR3C1 (0.48) NR3C1PGRNR3C2ARNPC1
SCHEMBL4157439 0.82 AR (0.69) NR3C1PGRNR3C2ARNPC1
SCHEMBL14092270 0.81 NR3C1 (0.73) NR3C1PGRNR3C2ARNPC1
SCHEMBL14092253 0.80 NR3C1 (0.54) NR3C1PGRNR3C2ARNPC1
SCHEMBL4160670 0.79 NR3C1 (1.00) NR3C1PGRNR3C2ARNPC1
SCHEMBL14092254 0.79 NR3C1 (0.53) NR3C1PGRNR3C2ARNPC1
SCHEMBL13802767 0.79 NR3C1 (0.78) NR3C1PGRNR3C2ARNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS COGHLAN MICHAEL JOSEPH 2009-06-11 US disclosed
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS COGHLAN MICHAEL JOSEPH 2009-06-11 US disclosed
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS COGHLAN MICHAEL JOSEPH 2009-06-11 US disclosed
US-7411072-B2 Tricyclic steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2008-08-12 US disclosed
US-7411072-B2 Tricyclic steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2008-08-12 US disclosed
US-7411072-B2 Tricyclic steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2008-08-12 US disclosed
US-20060063759-A1 Tricyclic steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY 2006-03-23 US disclosed
WO-2004052847-A2 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2004-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS NR5A1, NR3C2, NR3C1 NR3C1 3/4885PGR 54/4885NR3C2 2/4885
US-20060063759-A1 Tricyclic steroid hormone nuclear receptor modulators NR5A1, NR3C2, NR3C1 NR3C1 3/4885PGR 50/4885NR3C2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.